Risk factors
Theravance Biopharma (TBPH) risk factors
Item 1A of every Theravance Biopharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors47 risks6 new12 dropped20 reworded
Theravance Biopharma is heavily focused on the commercial performance and royalty streams of TRELEGY and YUPELRI.
Filed Mar 23, 2026 - FY2024 10-K risk factors53 risks
Theravance Biopharma faces concentrated revenue risk tied to YUPELRI sales and partnership performance with Viatris and Royalty Pharma. The company relies on continuous clinical development, single-source manufacturing, and navigating extensive regulatory and healthcare pricing frameworks. A Strategic Review Committee was formed in November 2024 to unlock shareholder value.
Filed Mar 07, 2025